<DOC>
	<DOCNO>NCT00033423</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness radiolabeled monoclonal antibody treat patient relapsed refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Treating Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose yttrium Y 90 ibritumomab tiuxetan administer combination rituximab patient relapse refractory low-grade , follicular , transform CD20-positive B-cell non-Hodgkin 's lymphoma ( NHL ) . - Determine toxicity different dos yttrium Y 90 ibritumomab tiuxetan patient treat regimen . - Determine frequency reversal bone marrow involvement NHL patient treat regimen . - Determine antitumor response patient treat regimen . OUTLINE : This multicenter , dose-escalation study yttrium Y 90 ibritumomab tiuxetan . Patients receive rituximab IV weekly week 1-4 . After 4 dos rituximab , patient without bone marrow involvement cellularity great 50 % expect receive rituximab IV weekly week 6 7 yttrium Y 90 ibritumomab tiuxetan IV 10 minute final dose rituximab ( day 43 ) . Cohorts 5-6 patient receive escalate dose yttrium Y 90 ibritumomab tiuxetan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 4 5 3 6 patient experience dose-limiting toxicity . Patients follow 6 12 week , every 2-3 month 2 year , every 6 month 2 year . PROJECTED ACCRUAL : Approximately 6-30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm lowgrade , follicular , transform CD20positive Bcell nonHodgkin 's lymphoma ( NHL ) Relapsed prior chemotherapy OR chemotherapyresistant disease Failed least 1 prior chemotherapy regimen CD20positive Bcell population lymph node bone marrow International Working Formulation A ( small lymphocytic lymphoma ) transform NHL Bone marrow involvement lymphoma le 25 % bilaterally No impair bone marrow reserve define least 1 follow criterion : Prior myeloablative therapy bone marrow transplantation peripheral blood stem cell rescue Platelet count le 100,000/mm3 Bone marrow cellularity great 15 % Marked reduction bone marrow precursor one cell line ( e.g. , granulocytic , megakaryocytic , erythroid ) Failed prior stem cell collection No CNS lymphoma , chronic lymphocytic lymphoma , HIV AIDSrelated lymphoma No diffuse small lymphocytic/marginal zone lymphoma lymphocyte count great 5,000/mm^3 No pleural effusion NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 19 Performance status : WHO 02 Life expectancy : At least 6 month Hematopoietic : See Disease Characteristics Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hematocrit great 30 % Hemoglobin great 9.0 g/dL Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study participation No antimurine antibody reactivity prior exposure murine antibody proteins No primary malignancy No serious nonmalignant disease infection would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior radioimmunotherapy Prior rituximab allow 6 month progression objective response At least 6 week since prior rituximab At least 3 week since prior filgrastim ( GCSF ) sargramostim ( GMCSF ) Recovered prior immunotherapy Chemotherapy : See Disease Characteristics No prior fludarabine At least 3 week since prior anticancer chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent chemotherapy Endocrine therapy : At least 3 week since prior anticancer endocrine therapy No concurrent highdose systemic corticosteroid ( e.g. , 50 mg prednisone single dose 50 mg less prednisone 6 dos ) Radiotherapy : No prior radiotherapy 25 % active bone marrow ( involved field regional ) At least 3 week since prior anticancer radiotherapy recover Surgery : At least 4 week since prior surgery ( except diagnostic surgery ) recover Other : No concurrent anticancer therapy Concurrent oral anticoagulant therapy allow platelet count least 30,000/mm3</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>